Postoperative Adjuvant Chemotherapy with CDDP+VDS for Non-small Cell Lung Cancer - A Randomized, Controlled Trial

Abstract

A randomized, controlled trial was performed to determine whether postoperative adjuvant chemotherapy with CDDP+VDS can improve the survival rate in patients with non-small cell lung cancer (NSCLC) undergoing curative or relatively non curative resection. Stage I patients were divided in Group A (CDDP+VDS and 2 years of 5-FU p.o.) and Group B (no treatment). Stage II, III patients were divided in Group C (2 courses of CDDP+VDS and 2 years of 5-FU p.o.) and Group D (2 years of 5-FU p.o. only). The numbers of patients in Groups A, B, C and D were 63, 66, 32 and 31 respectively. Postoperative 5-year-survival rates were 79.4% for Group A, 86.3% for Group B, 25.0% for Group C and 22.6% for Group D. Thus postoperative adjuvant chemotherapy with CDDP+VDS did not improve the 5-year survival rate.